0001562180-21-005125.txt : 20210803 0001562180-21-005125.hdr.sgml : 20210803 20210803160946 ACCESSION NUMBER: 0001562180-21-005125 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20210801 FILED AS OF DATE: 20210803 DATE AS OF CHANGE: 20210803 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Olwill Shane CENTRAL INDEX KEY: 0001875416 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37471 FILM NUMBER: 211139804 MAIL ADDRESS: STREET 1: C/O PIERIS PHARMACEUTICALS, INC. STREET 2: 255 STATE STREET, 9TH FLOOR CITY: BOSTON STATE: MA ZIP: 02109 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: PIERIS PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001583648 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 300784346 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 255 STATE STREET STREET 2: 9TH FLOOR CITY: BOSTON STATE: MA ZIP: 02109 BUSINESS PHONE: 857-246-8998 MAIL ADDRESS: STREET 1: 255 STATE STREET STREET 2: 9TH FLOOR CITY: BOSTON STATE: MA ZIP: 02109 FORMER COMPANY: FORMER CONFORMED NAME: Marika Inc. DATE OF NAME CHANGE: 20130805 3 1 primarydocument.xml PRIMARY DOCUMENT X0206 3 2021-08-01 0 0001583648 PIERIS PHARMACEUTICALS, INC. PIRS 0001875416 Olwill Shane C/O PIERIS PHARMACEUTICALS, INC. 255 STATE STREET, 9TH FLOOR BOSTON MA 02109 false true false false Chief Development Officer Common Stock 4638.00 D Stock Option (right to buy) 2.00 2024-12-17 Common Stock 145000.00 D Stock Option (right to buy) 1.52 2026-02-12 Common Stock 100000.00 D Stock Option (right to buy) 1.99 2027-02-23 Common Stock 56250.00 D Stock Option (right to buy) 0.00 2028-02-20 Common Stock 90000.00 D Stock Option (right to buy) 3.09 2029-02-26 Common Stock 82000.00 D Stock Option (right to buy) 3.15 2030-02-27 Common Stock 90000.00 D Stock Option (right to buy) 2.50 2031-03-04 Common Stock 150000.00 D The option has fully vested. The option vested as to 25% of the option shares on February 20, 2019 and vests as to an additional 6.25% of the option shares at the end of each successive three-month period thereafter. The option vested as to 25% of the option shares on February 26, 2020 and vests as to an additional 6.25% of the option shares at the end of each successive three-month period thereafter. The option vested as to 25% of the option shares on February 27, 2021 and vests as to an additional 6.25% of the option shares at the end of each successive three-month period thereafter. The option vested as to 25% of the option shares on March 4, 2022 and vests as to an additional 6.25% of the option shares at the end of each successive three-month period thereafter. /s/ Megan Gates, Attorney-in-Fact 2021-08-03 EX-24 2 solwillpoa.txt SHANE OLWILL POA POWER OF ATTORNEY Know all by these present, that the undersigned hereby constitutes and appoints each of Stephen Yoder and Ahmed Mousa of Pieris Pharmaceuticals, Inc. and each of Megan Gates, Keunjung Cho, Amanda Mei, Ilse Johnson and Brenda Meyette of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., signing singly, with full power of substitution, the undersigned's true and lawful attorney-in-fact to: (1) execute for and on behalf of the undersigned, forms and authentication documents for EDGAR Filing Access; (2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such forms and authentication documents; (3) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer, director and/or 10% shareholder of the Company, Forms 3, 4 and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder; (4) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4 or 5 and timely file such form with the United States Securities and Exchange Commission and any stock exchange or similar authority; and (5) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney- in-fact, may be of benefit to, in the best interests of, or legally required by the undersigned, it being understood that the documents executed by such attorney- in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion. The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934, as amended. This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys- in-fact. IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed this 22nd day of July, 2021. /s/ Shane Olwill Signature Shane Olwill Print Name